NASDAQInformation TechnologySoftware - ApplicationSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage capital through equity sales and agreements | A supporting condition in FIREFLY NEUROSCIENCE INC's published investment case. The stated target is Maintain stable capital access without dilutive equity sales. | Under Pressure | Further termination of material agreements or heavy dilution | Material agreement terminated; $1.0M dilutive sale failed June 2026 8-K confirms termination of the $1.0M securities purchase agreement with an accredited investor. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 6 of last 6 quarters. Revenue grew from $43,000 in 2025-Q1 to $514,000 in 2026-Q2, showing a strong upward trajectory. Management's focus on strategic agreements aligns with this consistent revenue growth, indicating delivery on this priority. Delivery assessment Oct 24, 2026 |
Operating income improvement through cost management | It improved operating income by $491K in the same period. | Intact | operating loss worsens beyond -$2,501,000 after 2026-Q1 | Operating income: $-1.974M FY2026-Q2; GAAP. Published target: Operating loss better than -$2,010,000 in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 10, 2026-1,974,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f01d674f-d82e-4c21-9f02-41ceccf5c749. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 6 of last 6 quarters. Operating income loss improved from -$2,656,000 in 2025-Q3 to -$1,974,000 in 2026-Q2, indicating progress in cost management. The trajectory shows delivering improvement but operating losses remain significant. Delivery assessment Oct 24, 2026 |
Revenue growth through strategic agreements | A primary condition in FIREFLY NEUROSCIENCE INC's published investment case. The stated target is >= $485,000 revenue in 2026-Q1. | Intact | revenue falls below $412,000 in any quarter after 2026-Q1 | Revenue: $514,000 FY2026-Q2; GAAP. Published target: >= $485,000 revenue in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 10, 2026514,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f01d674f-d82e-4c21-9f02-41ceccf5c749. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 6 of last 6 quarters. Revenue grew from $43,000 in 2025-Q1 to $514,000 in 2026-Q2, showing a strong upward trajectory. Management's focus on strategic agreements aligns with this consistent revenue growth, indicating delivery on this priority. Delivery assessment Oct 24, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative growth, not an established durable compounder, because the company is loss-making and faces elevated risk. The three-to-six-month thesis is in a watch state, with recent performance well below its industry cohort but no fresh break reported.
The valuation model describes AIFF as carrying a durable premium of 2.65 times versus peers, while its expectations gap is negative at -1.04. Model confidence is low, so the premium and expectations signal are uncertain; the evidence does not establish that the valuation is cheap or that current expectations are easy to meet.
Near term, management has grown revenue from $43,000 in 2025-Q1 to $514,000 in 2026-Q2 and improved the operating loss, though the company remains significantly loss-making. Strategic agreements and cost control remain stated priorities, while private placements are an ongoing source of capital with mixed effects on financial stability. A CFO transition and terminated M&A activity add uncertainty, and recent financial performance remains weak.
Over the multi-year view, the thesis hinges on whether revenue growth continues and operating losses narrow without continued dependence on capital raising. Near term, Fed rate cuts could support technology-sector sentiment, while results and guidance from SAP, CRM, and NOW may signal whether that sector support persists or fades.
AIFF has evidence of revenue growth and some progress reducing losses, but it remains a loss-making, volatile business with weak recent performance and uncertain valuation signals. The 1-to-3-year thesis depends on sustained execution and improving financial stability. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.